Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Naloxone 5 mg Autoinjector
NCT05264493Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2020
- Primary completion
- Jan 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of naloxone in opioid overdose (3 arms), sponsored by Pfizer. Primary endpoints: Maximum observed plasma naloxone concentration and Area under the naloxone concentration versus time curve from time zero to the last collection time. Started Oct 2020; status: completed.
02
Drugs
naloxone
03
Conditions
opioid overdose
Beyond the preview
Go deeper on NCT05264493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05264493.